IRAK1BP1 and neoplasm: LCOs, as a preclinical tumor model with similar molecular characteristics to tumor samples while minimizing the confounding effects of miscellaneous cells on test results, can be combined with high-throughput RNA sequencing (RNA-Seq) to identify IRAK1BP1 as a novel disease predictor in lung adenocarcinoma (80).